Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Counsyl | RCV000412053 | SCV000486899 | likely pathogenic | Bardet-Biedl syndrome 12 | 2016-09-08 | criteria provided, single submitter | clinical testing | |
| Invitae | RCV001210422 | SCV001381908 | pathogenic | Bardet-Biedl syndrome | 2024-01-17 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gly361Valfs*22) in the BBS12 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 350 amino acid(s) of the BBS12 protein. This variant is present in population databases (no rsID available, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with Bardet-Biedl syndrome (PMID: 24611592). ClinVar contains an entry for this variant (Variation ID: 371339). This variant disrupts a region of the BBS12 protein in which other variant(s) (p.Arg675*) have been determined to be pathogenic (PMID: 20827784, 21642631). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
| Fulgent Genetics, |
RCV000412053 | SCV002813911 | pathogenic | Bardet-Biedl syndrome 12 | 2022-02-25 | criteria provided, single submitter | clinical testing | |
| Baylor Genetics | RCV000412053 | SCV004211706 | pathogenic | Bardet-Biedl syndrome 12 | 2023-02-08 | criteria provided, single submitter | clinical testing |